BridgeMD
The NIMBUS study: A study on inhalation therapy with liposomal amphotericin B and its distribution in the lungs in chronic pulmonary fungal infections.
EU CTIS ID: 2025-521770-34-00
What this study is testing
To assess the pulmonary deposition of liposomal amphotericin B, administered via nebulisation as Technetium-99m labelled AmBisome, aiming to assess intrapulmonary distribution and to provide arguments to optimize treatment design.
- Human Pharmacology (Phase I)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- The patient is at least 18 years old on the day of inclusion.
- The patients has been diagnosed with chronic pulmonary aspergillosis.
- There is no significant interference with standard care and follow-up.
You likely can't join if
- The patient is breastfeeding, or of childbearing potential and is pregnant, planning to become pregnant within 3 months of the SPECT imaging, unable to provide a negative pregnancy test at screening, or unwilling to use effective contraception during the study and for at least 3 months after the last SPECT scan.
- The patient is not able to lie supine in the scanner.
- The patient has previously reported intolerance to inhalation medication.
- The patient is unable to provide informed consent due to lack of decision-making capacity
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.